|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Geer RJ and Brennan MF: Prognostic
indicators for survival after resection of pancreatic
adenocarcinoma. Am J Surg. 165:68–72. 1995. View Article : Google Scholar
|
|
3
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kang MJ, Jang JY, Chang YR, Kwon W, Jung W
and Kim SW: Revisiting the concept of lymph node metastases of
pancreatic head cancer: Number of metastatic lymph nodes and lymph
node ratio according to N stage. Ann Surg Oncol. 21:1545–1551.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Picozzi VJ, Oh SY, Edwards A, Mandelson
MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS
and Kozarek RA: Five-year actual overall survival in resected
pancreatic cancer: A contemporary single-institution experience
from a multidisciplinary perspective. Ann Surg Oncol. 24:1722–1730.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okusaka T, Ikeda M, Fukutomi A, Ioka T,
Furuse J, Ohkawa S, Isayama H and Boku N: Phase II study of
FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic
pancreatic cancer. Cancer Sci. 105:1321–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dedey F, Wu L, Ayettey H, Sanuade OA,
Akingbola TS, Hewlett SA, Tayo BO, Cole HV, de-Graft Aikins A,
Ogedegbe G and Adanu R: Factors associated with waiting time for
breast cancer treatment in a teaching hospital in Ghana. Health
Educ Behav. 43:420–427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jooste V, Dejardin O, Bouvier V, Arveux P,
Maynadie M, Launoy G and Bouvier AM: Pancreatic cancer: Wait times
from presentation to treatment and survival in a population-based
study. Int J Cancer. 139:1073–1080. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raptis DA, Fessas C, Belasyse-Smith P and
Kurzawinski TR: Clinical presentation and waiting time targets do
not affect prognosis in patients with pancreatic cancer. Surgeon.
8:239–246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sanjeevi S, Ivanics T, Lundell L, Kartalis
N, Andrén-Sandberg Å, Blomberg J, Del Chiaro M and Ansorge C:
Impact of delay between imaging and treatment in patients with
potentially curable pancreatic cancer. Br J Surg. 103:267–275.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song H, Fang F, Valdimarsdóttir U, Lu D,
Andersson TM, Hultman C, Ye W, Lundell L, Johansson J, Nilsson M
and Lindblad M: Waiting time for cancer treatment and mental health
among patients with newly diagnosed esophageal or gastric cancer: A
nationwide cohort study. BMC Cancer. 17:22017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neal RD, Tharmanathan P, France B, Din NU,
Cotton S, Fallon-Ferguson J, Hamilton W, Hendry A, Hendry M, Lewis
R, et al: Is increased time to diagnosis and treatment in
symptomatic cancer associated with poorer outcomes? Systematic
review. Br J Cancer. 112 (Suppl 1):S92–S107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Perri T, Issakov G, Ben-Baruch G, Felder
S, Beiner ME, Helpman L, Hogen L, Jakobson-Setton A and Korach J:
Effect of treatment delay on survival in patients with cervical
cancer: A historical cohort study. Int J Gynecol Cancer.
24:1326–1332. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen J, Yang R, Lu Y, Xia Y and Zhou H:
Diagnostic accuracy of endoscopic ultrasound-guided fine-needle
aspiration for solid pancreatic lesion: A systematic review. J
Cancer Res Clin Oncol. 138:1433–1441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hewitt MJ, McPhail MJ, Possamai L, Dhar A,
Vlavianos P and Monahan KJ: EUS-guided FNA for diagnosis of solid
pancreatic neoplasms: A meta-analysis. Gastrointest Endosc.
75:319–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hikichi T, Irisawa A, Bhutani MS, Takagi
T, Shibukawa G, Yamamoto G, Wakatsuki T, Imamura H, Takahashi Y,
Sato A, et al: Endoscopic ultrasound-guided fine-needle aspiration
of solid pancreatic masses with rapid on-site cytological
evaluation by endosonographers without attendance of
cytopathologists. J Gastroenterol. 44:322–328. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Suzuki R, Lee JH, Krishna SG, Ramireddy S,
Qiao W, Weston B, Ross WA and Bhutani MS: Repeat endoscopic
ultrasound-guided fine needle aspiration for solid pancreatic
lesions at a tertiary referral center will alter the initial
inconclusive result. J Gastrointestin Liver Dis. 22:183–187.
2013.PubMed/NCBI
|
|
21
|
Hébert-Magee S, Bae S, Varadarajulu S,
Ramesh J, Frost AR, Eloubeidi MA and Eltoum IA: The presence of a
cytopathologist increases the diagnostic accuracy of endoscopic
ultrasound-guided fine needle aspiration cytology for pancreatic
adenocarcinoma: A meta-analysis. Cytopathology. 24:159–171. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eastern Cooperative Oncology Group. ECOG
performance status. http://ecog-acrin.org/resources/ecog-performance-statusJune
3–2015
|
|
23
|
International Union against Cancer, .
Sobin LH, Gospodrowicz MK and Wittekind CH: TNM Classification of
Malignant Tumours. 7th. New York, NY: Wiley-Liss; 2009
|
